Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Rakhi P. Naik is the Associate Director for the Division of Hematology at Johns Hopkins University. She also serves as Director of the Fellowship Hematology Track and Director of Organ Systems Foundation of Medicine (OSFM), the largest pre-clerkship course in the medical school. She holds an undergraduate degree in Biomedical & Electrical Engineering from Duke University, an M.D. with. Dr. Naik is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy.

Panayotis Ledakis is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Ledakis is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Appendix Cancer, Desmoplastic Small Round Cell Tumor, Anemia, Colorectal Cancer, and Ureteroscopy. Dr. Ledakis is currently accepting new patients.

Djordje Atanackovic is a Hematologist and a Hematologist Oncology provider in Baltimore, Maryland. Dr. Atanackovic is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Aaron Stonestrom is an Oncologist in Baltimore, Maryland. Dr. Stonestrom has been practicing medicine for over 10 years and is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Acute Myeloid Leukemia (AML), Agranulocytosis, Febrile Neutropenia, Childhood Acute Myeloid Leukemia, and Bone Marrow Aspiration.

Michael Streiff is a Hematologist in Baltimore, Maryland. Dr. Streiff is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism, Pancreaticoduodenectomy, and Bone Marrow Aspiration.

Bhargavi Pulluri is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Pulluri is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Schnitzler Syndrome, and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Pulluri is currently accepting new patients.

Carole Miller is an Oncologist in Baltimore, Maryland. Dr. Miller is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Familial Colorectal Cancer, and Muscle Invasive Bladder Cancer. Dr. Miller is currently accepting new patients.

Richard Schraeder is a Hematologist Oncology specialist and a Hematologist in Towson, Maryland. Dr. Schraeder is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Retroperitoneal Liposarcoma. Dr. Schraeder is currently accepting new patients.

Myo Min is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Min is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Colorectal Cancer, and Large-Cell Immunoblastic Lymphoma. Dr. Min is currently accepting new patients.